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Summary Levetiracetam (LEV) is a novel antiepileptic drug (AED) that has recently
obtained marketing authorisation for use in children. The purpose of this study was to
assess the efficacy, tolerability and retention rate of LEV in children with refractory
epilepsies. It is a retrospective multicentre observational study reporting the use of
LEV in 200 children, aged 0.3—19 years (median 9-years-old) over a 4-year period.
All of the patients included in the study had refractory epilepsy with a median age
of onset of epilepsy of 3 years (range 0—13 years). The 38% had failed and withdrawn 3
or more AEDs previously and 24% were taking at least 2 other AEDs in addition to LEV.
The 47% had focal, and 58% had symptomatic epilepsies. The LEV dose ranged from 8
to 100 mg/kg/day (mean 39 mg/kg). The study comprised 215 person years of LEV
exposure.
Results: LEV was well tolerated with a retention rate of 49% at 1 year. No serious
adverse events were reported with possibly related adverse events reported in only
24% of patients (mainly emotional or behavioural changes). At more than 2, 6 and 12
months, worthwhile improvement (>50% seizure reduction) was noted in 60, 40 and
32%, including seizure freedom in 14, 14 and 5%, respectively.
Conclusion: Our results confirm the efficacy and tolerability of LEV in children
with refractory epilepsies and demonstrate good response and retention rates at
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12 months. It represents the largest cohort of paediatric patients published so far on
LEV with a 1-year follow-up.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Levetiracetam(LEV) is anovel antiepileptic drugwith
a unique mechanism of action,1,2 proven efficacy
against partial and generalised seizures,3—8 good
tolerability and straight forward pharmacokinetics.9
There have been few studies of LEV use in chil-
dren, and most are retrospective. Although LEV has
been shown to be effective against both partial and
generalised epilepsy, with a response rate of up to
50% in children with partial epilepsies,10 most of the
studies contain small numbers and have a limited
follow-up period. This study reports the use of LEV in
200 paediatric patients with refractory epilepsies,
over a 4-year period. Our results confirm the effi-
cacy and tolerability of LEV in this population and
demonstrate good response and retention rates at
12 months.Methods
Children starting treatment with LEV from December
2001 to December 2004 were ascertained retrospec-
tively from hospital pharmacy and from paediatric
neurology databases in four tertiary referral paedia-
tric neurology departments in the Midlands, UK.
LEV was prescribed as an ‘‘add on therapy’’ for con-
trol of refractory epilepsies–—partial or generalised,
by a Consultant Paediatric Neurologist in each
centre.
A retrospective chart review using a standard
proforma to assess demographic data, aetiology,
epilepsy syndrome, seizure frequency, medication
dosage, concomitant AEDs, efficacy and adverse
events was recorded at more than 2, 6 and 12
months. Data were analysed using Excel on an inten-
tion to treat basis.Table 1 Previous antiepileptic medication
Number of AEDs Percent of patients
0—2 24
3—5 56
>5 20
The 76% of children commenced on LEV had been on at least 3
AEDs in the past. This is an indication of the intractable nature
of the epilepsies studied in our group.Results
Two-hundred children were included in the study.
The 59%weremale. Themajority of our children had
early onset epilepsies with a median age of onset of
epilepsy of 3 years (range 0—13 years). There was
no significant difference between the types of
epilepsies treated. The 47% had focal, and 58%
had symptomatic epilepsies. Patients commenced
on LEV, were aged between 0.3 and 19 years (median
9-years-old).The intractable nature of the epilepsies treated
with LEV is demonstrated by the number of patients
who had failed or withdrawn previous AEDs
(Table 1). The 76% of children commenced on LEV
had been on at least 3 AEDs in the past.
The study comprised 215 person years of LEV
exposure. LEV dose ranged from 8 to 100 mg/kg/
day (mean 39 mg/kg).
Brain neuroimaging (either MRI or CT) reports
were obtained in 185/200 patients. One-hundred
and sixteen (58%) were abnormal (20 with cerebral
atrophy, 7 neuro-migrational disorders, 6 cortical
dysplasias, 5 hippocampal sclerosis, 4 tuberous
sclerosis, 74 (37%) with other abnormalities. The
69 (34.5%) scans were reported as normal.
Seven children achieved LEV monotherapy. Of
those patients that achieved monotherapy, five
had generalised epilepsies and the majority had
been on at least two AEDs in the past (mean 3,
range 1—5).
Most patients required at least 1 other AED in
addition to LEV and there was no particular prefer-
ence for a specific combination of AEDs across the
centres (Table 2).
Possibly LEV related adverse events were reported
in 24%. The most frequent adverse-effects involved
emotional or behavioural changes (Table 3). Adverse
events usually appeared within the first 5 months
after treatment initiation. They were not dose-
dependent and mostly mild. No serious adverse
events (death or events requiring hospital admission
or a prolongation of hospital admission) were
reported. Adverse events generally resolved without
medication withdrawal, but if not, did resolve when
the medication was stopped. Only 8 of the 200
patients (4%) withdrew from LEV because of adverse
events alone.
Some papers have reported increased behavioural
adverse events in children and patients with a history
of prior behavioural problems.11—13 Pre-existing
behavioural problems were documented in 8%
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Table 2 Concomitant antiepileptic medication
Percent of patients
Number of concomitant AEDs
0 7
1 48
2 39
3 6
Type of concomitant AED
Lamotrigine 33
Valproate 23
Benzodiazepines 21
Topiramate 19.5
Carbamazepine 14.5
Othersa 15.5
Only seven children achieved LEV monotherapy. The majority
of children were on a combination of one or two concomitant
AEDs. There was no preference for any particular AED in
combination with LEV.
a Gabapentin, phenobarbitone, vigabatrin, prednisalone,
zonisamide.
Table 4 Reason for discontinuation of LEV
Number of
children
(n = 200)
Percent
87 43.5
Adverse events alone 8 4
Adverse events and
inadequate seizure control
20 10
Inadequate seizure
response alone
56 28
Othera 3 1.5
Seizure free post-hemispherotomy. Seizure free on introduc-
tion of the ketogenic diet.
a Maternal withdrawal of medication for alternative thera-
pies.(17/200) of children in our study. Of those 17 children
only 7 (41%) reported behaviour as a problems on
follow-up. The 14% of children who did not have pre-
existingbehaviouraldifficultiesdevelopednewbeha-
vioural problemswhile on LEV. As we did notmeasure
the extent of any behavioural problems we cannot
tell if they were worsened on LEV. Therefore, unlike
other studieswewere unable to detect if behavioural
adverse events were more likely to occur in children
with pre-existing behavioural difficulties.
Eighty-seven children discontinued LEV; discon-
tinuation was due to inefficacy alone in 56 (28%),
inefficacy and adverse events in 20 (10%), adverse
events alone in 8 (4%) and in 3 for other reasons
(parental withdrawal, seizure freedom on introduc-
tion of ketogenic diet, seizure freedom post-hemi-
spherotomy) (Table 4). The 22/54 children had an
increase in their seizures on LEV. LEV was most likely
to be discontinued within the first 3 months of
starting the medication (Graph 1).
Data were analysed on 200,195 and 158 children
at 2, 6 and beyond 12 months, respectively. The 79%
(158/200) patients were followed up beyond 12Table 3 Adverse events
Adverse events Number of patients (n = 48)
Emotional lability 15 (7.5%)
Aggression 12 (6%)
Depression 6 (3%)
Somnolence 5 (2.5%)
Othera 10 (5%)
Adverse events were reported in 48/200 (24%) of children. The
majority were behavioural in nature.
a Nausea, vomiting, weight change, headache, and rash.months. The 42 children were not followed up at
12 months due to: insufficient data collection,
transfer to adult services, and insufficient length
of time on LEV. LEV retention for more than 1 year
was 49% (76/158). The mean length of time on LEV
was 13 months, range (3 weeks—46 months).
Seizure response rates were highest within the
first 2 months, with a worthwhile improvement
(>50% seizure reduction) of 60% at 2 months, includ-
ing seizure freedom in 14%. Seizure response rates
remained high at 6 months with 40% improved and
14% seizure free. These figures dropped to 32%
beyond 12 months with a seizure freedom rate of
5% (Graph 2). Those patients who had an early
response tended to maintain that response over
the 12 month period.Discussion
LEV has recently been awarded marketing author-
ization in the UK for its use in children over 4 years ofGraph 1 The 87 children discontinued LEV in total. The
11/87 (9.8%) discontinued LEV within the first month of
commencing medication. The % of children who discon-
tinued LEV decreased over time. The highest discontinua-
tion rates of LEV are within the first 3 months of starting
the medication.
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Graph 2 Percentage of children who started LEV and
were available for follow-up at more than 2 months, 6
months, and 12 months, who had >50% reduction in
seizure rate, and who were seizure free.age with partial onset epileptic seizures with or
without secondary generalisation. The mechanism
of action of LEV remains to be fully elucidated. In
vitro studies show that LEV affects intraneuronal
Ca2+ levels by partial inhibition of N-type CA2+ cur-
rents and by reducing the release of Ca2+ from
intraneuronal stores. In addition it partially reverses
the reductions in GABA-and glycine-gated currents
induced by zinc and b-carbolines.
LEV has been shown to be effective and well
tolerated in children with both partial and general-
ised epilepsies that are difficult to treat.2,14,15
LEV is very straight forward to manage as it has
favourable pharmacokinetic characteristics: it has a
high oral bioavailability, linear pharmacokinetics
and predictable plasma levels, and exhibits no sig-
nificant drug interactions.9
This is particularly important in children with
intractable epilepsies as many have significant neu-
ropsychiatric co-morbidities including attention def-
icit/hyperactivity disorder, autisum spectrum
disorders, depression, anxiety, and thought disor-
ders. In our study 69% of the patients had co-existent
neuropsychiatric disorders or learning difficulties.
Only 13.5%hadLEVwithdrawndue to adverse events.
The limitations inherent indata collectionwith retro-
spective studiesmean it is difficult to retrospectively
attribute all of these changes to the addition of an
AED alone. Based on published data from prospec-
tive, chronic dosing studies, phenobarbitone and
topiramate have the highest potential for causing
cognitive dysfunction.14 Although neurobehavioural
changes in children with epilepsy may be multifac-
torial in nature, it is important to monitor the cog-
nitive effect of the addition of an AED. A muticentre
prospective study is required to fully asses the effect
of LEV on behaviour and cognition.
It has been reported that neurobehavioural
adverse events are more common in those childrenwith pre-existing behavioural problems but we were
unable to demonstrate that in our study.15—17 Pre-
existing behavioural problems were documented in
8% (17/200) of children in our study. Of those 17
children only 7 (41%) reported behaviour as a pro-
blems on follow-up. Due to the inherent limitations
of collection of retrospective data, we are unable to
comment on whether this is a true improvement or
not. A prospective study to highlight the effect of
LEV on this subgroup of patients is required.
Continuation rates were a good indicator of effi-
cacy and tolerability. Our results concur with other
studies showing an effective early response rate and
tolerability of LEV in children with intractable epi-
lepsies.18,19 At 2 and 6 months worthwhile improve-
ment (>50% seizure reduction) was noted in 60 and
40%, respectively, including seizure freedom in 14%
up to 6 months.
There are a limited number of studies looking at
retention rates of LEV in intractable epilepsies for
more than 12 months.20,21 In this study, the reten-
tion rate at more than 12 months was 49%. The 32%
of children on LEV for more than 12 months had a
>50% improvement in seizure control including a
seizure freedom rate of 5%. This is similar to or
better than retention rates for add-on therapy with
other second line AEDs: Topirimate, Lamotrogine
and Gabapentin.22 The reasons for the discrepancy
between retention rates and response rates are
difficult to explain retrospectively. It may indicate
that patients remained on LEV for beneficial reasons
other than seizure control.23,24 These benefits need
to be studied in more detail prospectively.
Our study confirms the efficacy and tolerability of
LEV in children with intractable epilepsies beyond a
year. Mutlicentre prospective studies are required
to look at the long-term efficacy of LEV beyond this
period and to ascertain the relationship between
children with pre-existing behavioural difficulties
and the potential neurobehavioural adverse effects.References
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